Catalyst Event
Johnson & Johnson (JNJ) · Other
From Akros SCHK HK-U.S. Tech 100 Index (ASHUSTC)
6/3/2026, 12:00:00 AM
Johnson & Johnson announced on June 3, 2026, that its monoclonal antibody, nipocalimab, met the primary endpoint in the Phase 2 JASMINE study for SLE; positive clinical data for a major pipeline candidate is estimated to have a 5-10% market impact, expected.
Korean Translation
2026년 6월 3일, Johnson & Johnson은 니포칼리맙의 2상 JASMINE 연구에서 1차 평가변수를 충족했다고 발표함. 주요 파이프라인의 긍정적인 임상 데이터는 5-10%의 시장 영향을 미칠 것으로 예상됨.
Related Recent Events
Xiaomi Corporation (1810) · Earnings Release
Q2 2026 earnings release is scheduled. A low market impact is estimated as the specific financial results are not yet disclosed.
8/26/2026, 12:00:00 AM
Amazon.com Inc (AMZN) · Earnings Release
Amazon's Q2 2026 earnings release is expected on July 30, 2026. The company guided for net sales between $194.0 billion and $199.0 billion. Low importance is assigned as the market reaction has not yet occurred expected.
7/30/2026, 12:00:00 AM
Meta Platforms Inc (META) · Earnings Release
Meta Platforms is expected to release its Q2 2026 financial results after market close on July 29, 2026. Due to historical volatility during earnings for mega-cap tech stocks, a high price impact (>10%) is expected.
7/29/2026, 12:00:00 AM
Lam Research Corp (LRCX) · Earnings Release
Lam Research is expected to report its Q4 2026 earnings on July 29, 2026. Analysts forecast an EPS of approximately $1.65-$1.68. Market impact is estimated at Medium as earnings reports typically drive significant price volatility, scheduled.
7/29/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet Q2 2026 earnings release scheduled for July 22, 2026, with analysts forecasting EPS of approximately $2.85-$2.87 forecasted.
7/22/2026, 12:00:00 AM
International Business Machines Corp (IBM) · Earnings Release
IBM's Q2 2026 earnings announcement is scheduled for July 22, 2026, scheduled
7/22/2026, 12:00:00 AM